Low Injection Site Pain

PRINT THIS PAGE

In clinical trials, CIMZIA had a low rate of injection site pain with less than 2% of patients experiencing stinging and/or burning.^1-4

Click to enlarge

Anaphylaxis or serious allergic reactions may occur. Hypersensitivity reactions have been reported rarely following CIMZIA administration

Important Safety Information
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

NEXT: Administration by a Healthcare Professional »

Indication
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

Important Safety Information
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

*The CIMZIA Co-Pay Savings Card Program is valid for out-of-pocket expenses for CIMZIA for up to 17 uses. The CIMZIA Co-Pay Savings Card Program is not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), private insurance in the Commonwealth of Massachusetts, or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

medication guide & prescribing information

important safety information regarding fungal infections

For more information 1-866-4-CIMZIA (1-866-424-6942)

References:

Schreiber S, Khaliq-Kareemi M, Lawrence IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
Sandborn WJ, Feagan BG, Stoinov S, et al; for the PRECiSE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;375:228-238.
Sandborn W, Lichtenstein G, Schreiber S, Feagan B. The long-term, 30 months, efficacy and tolerability of certolizumab pegol therapy for Crohn's disease. Poster presented at: American College of Gastroenterology Annual Meeting; October 3-8, 2008; Orlando, FL.
Abreu MT, Sandborn W, D'Haens G, et al. Certolizumab pegol is efficacious in Crohn's disease patients who have failed infliximab regardless of concomitant therapy or reason for failure. Poster presented at: American College of Gastroenterology Annual Meeting; October 3-8, 2008; Orlando, FL.

SITEMAP

Home

CIMZIA Key Facts

Clinical Trials

Structure of CIMZIA

PEGylation Technology

Dosing and Administration

Clinical Setting

Safety Information

Contact a UCB Rep

For US Healthcare Professionals

CIMZIA^®, CIMplicity™, CIMpay^® are trademarks of the UCB Group of Companies.
OXO, GOOD GRIPS, and the associated logos are trademarks of Helen of Troy Limited and are used under license.
Trademarks or products listed are held by their respective trademark owners.